Results 91 to 100 of about 4,266 (228)

Sclerostin antibodies as novel anabolic therapy for osteoporosis

Остеопороз и остеопатии, 2019
Osteoporosis medications are dividedinto two groups: those inhibiting bone resorption and formation (bisphosphonates and denosumab), and those stimulating bone formation i.e. having an anabolic effect. The latter include teriparatide, parathyroid hormone
Elizaveta O. Mamedova, Tatiana A. Grebennikova, Zhanna E. Belaya, Liudmila Y. Rozhinskaya   +3 more
doaj   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 139-149, July 2026.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source

Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study

Journal of Endocrinological Investigation
The real-world effectiveness of switching from denosumab to romosozumab remains controversial. Sequential therapy with romosozumab was shown to be associated with inadequate suppression of bone resorption and there was anecdotal evidence of major ...
A. Piasentier, A. Fanti, M. F. Birtolo, W. Vena, R. Colle, L. Gentile, S. Jaafar, A. Bossi, A. Lania, G. Mazziotti   +9 more
semanticscholar   +1 more source

Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial

, 2020
International audienceThe bone-forming agent romosozumab is a monoclonal antibody that inhibits sclerostin, leading to increased bone formation and decreased resorption.
Horlait, Stéphane, Chapurlat, Roland, Betah, Donald, Eriksen, Erik, Chavassieux, Pascale, Boyce, Rogely Waite, Brown, Jacques, Libanati, Cesar, Shi, Yifei   +8 more
core   +2 more sources

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

, 2019
UNLABELLED: Romosozumab is a therapy that stimulates bone formation and reduces bone resorption. In this study of postmenopausal women with low BMD, a second course of romosozumab following a period off treatment or on denosumab increased or maintained ...
Libanati, C., Massari, F., Palacios, S., Maddox, J., Yan, C., Kendler, D.L., Grauer, A., Gielen, E., Yue, S., Bone, H.G., Dinavahi, R.V.   +10 more
core   +1 more source

Secondary Publication: Use of Romosozumab Against Osteoporosis

Tokyo Women's Medical University Journal
In recent years, osteoporosis has become a significant issue in developed countries. Romosozumab, which was introduced in 2019, is a relatively novel drug used for osteoporosis treatment.
Ayako Tominaga, Keiji Wada, Ken Okazaki
doaj   +1 more source

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts

, 2023
Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and ...
Melanie L. Rietveld, Pigeaud, Karina E., Karina E. Pigeaud, Nathalie Bravenboer, Aster F. Witvliet, de Vries, Teun J, Ton Schoenmaker, Zhang, Chen, Jolanda M. A. Hogervorst, Witvliet, Aster F, Bravenboer, Nathalie, Hogervorst, Jolanda M A, Hogervorst, Jolanda M.A., Rietveld, Melanie L, Schoenmaker, Ton; id_orcid, Rietveld, Melanie L., Schoenmaker, Ton, Witvliet, Aster F., Pigeaud, Karina E, Chen Zhang, Tim Forouzanfar, Teun J. de Vries, Forouzanfar, Tim, de Vries, Teun J.   +23 more
core   +1 more source

Mechanical Phenotyping of MG63s Following Vibrational Stimulation

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Mechanical Phenotyping of MG63s Following Vibrational Stimulation, *Mr. Rui Pedro Pereira Sousa, Prof Stuart Reid, Prof Matthew J. Dalby, Dr. Melanie Jimenez and *Dr. Peter G. Childs. Summary of the use of a high throughput mechanical phenotyping technique, Real‐Time Deformability Cytometry (RT‐DC) to observe mechanical changes in an osteogenic model ...
Rui Pedro Pereira Sousa, Stuart Reid, Matthew J. Dalby, Melanie Jimenez, Peter G. Childs   +4 more
wiley   +1 more source

Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study

Journal of General and Family Medicine, Volume 27, Issue 3, May 2026.
ABSTRACT Background This study aimed to examine the management of bisphosphonate (BP) therapy for osteoporosis in Japan, focusing on treatment duration, dual‐energy X‐ray absorptiometry (DXA) assessment status, therapy despite renal impairment, and history of atypical femoral fracture (AFF).
Taku Harada, Shintaro Kosaka
wiley   +1 more source

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study

, 2020
BACKGROUND: Romosozumab is an antibody that binds and inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption. A double-blinded, randomized, phase-2, dose-finding trial was performed to evaluate the effect of romosozumab on ...
Bhandari M., Schemitsch E.H., Karachalios T., Sancheti P., Poolman R.W., Caminis J., Daizadeh N., Dent-Acosta R.E., Egbuna O., Chines A., Miclau T.
core   +1 more source